Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer
Open Access
- 1 June 2017
- journal article
- review article
- Published by Elsevier in Journal of Molecular Biology
- Vol. 429 (12) , 1767-1786
Abstract
No abstract availableKeywords
Funding Information
- Institute of Cancer Research (ICR) (C36478/A19281)
- Cancer Research UK
This publication has 125 references indexed in Scilit:
- Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsMolecular Systems Biology, 2013
- A predictive pharmacokinetic–pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combinationCancer Chemotherapy and Pharmacology, 2013
- Cancer heterogeneity: implications for targeted therapeuticsBritish Journal of Cancer, 2013
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to ChemotherapyFrontiers in Oncology, 2013
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling NetworksCell, 2012
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast CancerCell, 2012
- Targeting Src family kinases in anti-cancer therapies: turning promise into triumphTrends in Pharmacological Sciences, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Phosphoproteomics: Unraveling the Signaling WebMolecular Cell, 2008